Remove 2008 Remove Conditions Remove Microdosing
article thumbnail

Research Shows Strong Support for Natural Therapeutics

Veriheal

He is said to have microdosed with LSD for the last 25 years of his life, passing away on April 29, 2008. Psilocybin, which is the primary chemical compound in what many call magic mushrooms , or shrooms, has gained significant traction and attention as a potential treatment for depression, anxiety, and other conditions.

Therapy 98
article thumbnail

Oregon is Setting the Foundation for its Psilocybin Therapy Program

Veriheal

A psychedelic therapy program like Oregon’s could help provide relief to millions suffering from conditions that currently don’t have effective treatments. Albert Hoffman was said to have spent the last 25 years of his life microdosing LSD. Mr. Hoffman lived to be 102 years old, passing away in April of 2008.

Therapy 98
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Here’s What Neuroimaging Can Tell Us About the Psychedelic Experience

SpeedWeed

Feduccia 2008): Ph.D. In her study published in the April 2020 issue of Biological Psychiatry: Cognitive Neuroscience and Neuroimaging , Bershad wanted to investigate the recent trend of microdosing LSD and analyze if there’s any scientific merit to the practice. Here are just a few interesting research studies. researcher Allison A.

article thumbnail

UW-Madison Is Diversifying Psychedelic Research

Veriheal

Hoffman lived a long life, reportedly microdosing with LSD during the last three decades or so of it until his death on April 29, 2008 at age 102. From the time that LSD and psilocybin were discovered, they were actively researched via thousands of studies. Unlike studies of the past, these will prioritize diversity among participants.

Therapy 98
article thumbnail

Psychedelic Invest’s 100 Most Influential People in Psychedelics List

Cannabis Law Report

David John Nutt is an English neuropsychopharmacologist specialising in the research of drugs that affect the brain and conditions such as addiction, anxiety, and sleep. Paul is the author of the book Microdosing Psychedelics: A Practical Guide to Upgrade Your Life and the founder and CEO of Third Wave and co-founder of Synthesis.